
Book an Appointment

GLP-1 weight loss injections, including Semaglutide and Tirzepatide, can support your weight loss goals by helping you feel fuller, reducing appetite, and making it easier to follow a nutrition plan. Results vary and this approach works best alongside healthy habits like protein-focused meals, daily movement, engagement in our Salt. lif app, and consistent sleep.
Semaglutide and Tirzepatide are prescription medications, and they are not right for everyone. Do not start GLP-1 therapy if you:
Tell your provider about any history of gallbladder disease, kidney disease, or diabetic retinopathy, and about every medication you take, including insulin and other diabetes medications. Your intake and labs are reviewed by a licensed provider before anything is prescribed.
Weight loss goes better when your energy holds up. These are the things clients most often add.
Both. Rather than offering medication alone, our packages combine Semaglutide or Tirzepatide with Boost IV therapy, Lipo-B injections, NAD+ support, and guided nurse follow-up, helping clients experience faster progress, better energy, and long-term success.
Many clients want more than weight loss. They want energy, metabolic support, and healthy aging while they are in a calorie deficit. NAD+ supports cellular energy and fat metabolism alongside the medication.
Both are GLP-1 medications that help you feel fuller and reduce appetite. Tirzepatide is the stronger option. Your provider helps you choose based on your intake, labs, health history, and goals.
Yes. Labs are required before you start, and your provider reviews your medical intake and lab work to prescribe safely. If you do not have recent labs, your SALT nurse can draw them at your visit for $169. The baseline panel also gives you something to measure progress against.
Most clients continue on a maintenance or taper plan guided by their nurse. Single vials are available for refills once you are on a program.
Yes. We accept HSA cards, and we provide an itemized receipt for every visit.